363166-11-4

Upstream product

• 149517-92-0 ethyl 4-bromo-3,5-diethoxybenzoate 
• 363166-41-0 4-bromo-3,5-diethoxybenzoic acid 
• 16534-12-6 3,5-dihydroxy-4-bromobenzoic acid 
• 363166-42-1 (4-bromo-3,5-diethoxyphenyl)methanol 

Relevant academic research and scientific papers

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

PYRIMIDINE AND QUINAZOLINE DERIVATIVES

This invention is concerned with compounds of the formula ( l ) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES

This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES

This invention is concerned with compounds of the formulaand pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Pyrimidine, quinazoline, pteridine and triazine derivatives

This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Synthesis of ferrocenethiols containing oligo(phenylenevinylene) bridges and their characterization on gold electrodes

Ferrocene-terminated oligo(phenylenevinylene) (OPV) methyl thiols have been prepared by orthogonal coupling of phenylene monomers. Ethoxy substituents on the phenyl rings improve the solubility of OPV, enabling the synthesis of longer oligomers. Self-assembled monolayers containing a mixture of a ferrocene OPV methyl thiol and a diluent alkanethiol were deposited on gold. A cyclic voltammetric study of monolayers containing oligomers of the same length with and without ethoxy solubilizing groups reveals that both solubilized and unsolubilized oligomers form well-packed self-assembled monolayers. Changing the position of the solubilizing groups on an oligomer chain does not preclude packing of the oligomer in the monolayer. Conventional chronoamperometry, which can be used to measure rate constants up to ～104 S-1, is too slow to measure the electron-transfer rate through these oligomers over distances up to 35 A. OPV bridges are expected to be highly conjugated unlike oligo(phenyleneethynylene) bridges, which may be only partially conjugated because of rotation of the phenyl rings about the ethynylene bonds. Because of its high conjugation, OPV may prove useful as a molecular wire.